Archimedis Digital, a digital transformation partner for life sciences and healthcare organisations, has released its flagship report titled State of Digital Transformation in Indian Pharma 2025 (Quality Edition), highlighting how pharmaceutical companies in India are gradually shifting towards digital quality ecosystems.

According to the report, India’s biopharmaceutical sector, one of the world’s largest suppliers of generic medicines and an emerging hub for novel drug research, is at a crucial turning point. Increasing regulatory scrutiny, rising process complexity and growing global competition are compelling companies to transition from traditional paper-based systems to integrated, data-driven digital platforms.

While the transition remains uneven, the findings indicate that the industry is preparing to build a strong digital data foundation capable of supporting advanced technologies such as Artificial Intelligence (AI) and Machine Learning (ML) for quality management and operational efficiency.

The study notes that companies adopting a comprehensive and outcome-driven digital strategy are already witnessing tangible benefits. These include faster regulatory compliance, quicker product-to-market timelines, improved decision-making and greater operational flexibility—factors that enhance competitiveness in global pharmaceutical markets.

Commenting on the findings, Duraisamy Rajan Palani, Founder and CEO of Archimedis Digital, said, “The digital transformation has become a strategic necessity for life sciences companies operating in increasingly complex regulatory and technological environments. The organisations must treat digitalisation as a foundation for long-term growth, resilience and differentiation.”

The report also highlights emerging technology priorities across the industry. Cloud computing, data analytics, automation, cybersecurity and AI/ML are now widely recognised as key drivers of efficiency and quality excellence.

In terms of adoption levels, the report reveals that most Indian pharmaceutical companies are currently in the mid-stages of their digital transformation journey. About 55.6 percent of organisations have partially implemented digital systems, while 33.3 percent have achieved significant or near-complete digital transformation. Only 2.2 percent have not started the process, and 8.9 percent are still in the planning phase.

Pharma companies are also gradually moving beyond isolated technology deployments towards embedding digital capabilities within their core business strategies. Although more than 88 percent of organisations have initiated digital quality assurance and quality control (QA/QC) initiatives, only about one-third have reached enterprise-level digital maturity, indicating the need for more integrated transformation roadmaps.

The report further notes a shift in how companies view digitalisation. Earlier seen primarily as a cost-reduction measure, digital transformation is increasingly being recognised as a critical enabler of quality, compliance and regulatory confidence. While 40 percent of organisations still identify cost savings as a key benefit, many now prioritise improved audit readiness and stronger data integrity.

Workforce and demographic shifts are also influencing digital adoption. As experienced personnel retire and knowledge gaps emerge, companies are prioritising systems that support knowledge centralisation and continuity. User-friendly and interoperable digital platforms, particularly integrated Quality Management Systems (QMS), are becoming essential for faster onboarding, consistent training and long-term knowledge retention.

At the same time, evolving drug development—especially in areas such as biologics and combination therapies—along with stricter Good Manufacturing Practice (GMP) requirements is creating new operational complexities. Legacy systems and integration challenges remain key barriers, but technologies like electronic batch manufacturing records (eBMRs) and laboratory automation are emerging as critical tools to improve accuracy and process control.

Palani emphasised that successful digital transformation in pharmaceutical quality goes beyond technology adoption and requires alignment of people, processes and organisational culture. He noted that companies that invest early in unified and intelligent digital ecosystems will be better positioned to define the next phase of innovation and quality excellence in the pharmaceutical industry.